Abstract-ATP-sensitive K ϩ channels (K ATP ) contribute to vasomotor regulation in some species. It is not fully understood the extent to which K ATP participate in regulating vasomotor tone under physiological and pathophysiological conditions in the human heart. Arterioles dissected from right atrial appendage were studied with video microscopy, membrane potential recordings, reverse transcription-polymerase chain reaction, and immunohistochemistry. Hypoxia produced endothelium-independent vasodilation and membrane hyperpolarization of vascular smooth muscle cells, both of which were attenuated by glibenclamide. Aprikalim, a selective K ATP opener, also induced a potent endothelium-independent and glibenclamide-sensitive vasodilation with membrane hyperpolarization. Reverse transcription-polymerase chain reaction detected mRNA expression for K ATP subunits, and immunohistochemistry confirmed the localization of the inwardly rectifying Kir6.1 protein in the vasculature. In patients with type 1 or type 2 diabetes mellitus (DM), vasodilation was reduced to both aprikalim (maximum dilation, DM(ϩ) 90Ϯ2% versus DM(Ϫ) 96Ϯ1%, PϽ0.05) and hypoxia (maximum dilation, DM(ϩ) 56Ϯ8% versus DM(Ϫ) 85Ϯ5%, PϽ0.01) but was not altered to sodium nitroprusside or bradykinin. Baseline myogenic tone and resting membrane potential were not affected by DM. We conclude that DM impairs human coronary arteriolar dilation to K ATP opening, leading to reduced dilation to hypoxia. This reduction in K ATP function could contribute to the greater cardiovascular mortality and morbidity in DM. 
Ϫ5 mol/L), confirming integrity of endothelial function. 7 Endothelin-1 (Ϸ10 Ϫ10 mol/L) or acetylcholine (Ϸ5ϫ10 Ϫ7 mol/L) [7] [8] [9] 11, 12 was, if needed, added to adjust basal tone to a consistent level between 30% to 60% of passive diameter.
Aprikalim Treatment
After constriction, vasodilation to cumulative increases in the concentration of aprikalim (10 Ϫ10 to 10 Ϫ5 mol/L, a selective K ATP opener) was studied in the presence and absence of N -nitro-L-arginine methyl ester (L-NAME) (10 Ϫ4 mol/L, an NO synthase inhibitor), indomethacin (10 Ϫ5 mol/L, a cyclooxygenase inhibitor), glibenclamide (10 Ϫ6 mol/L, a selective K ATP blocker), or mechanical endothelial denudation. [7] [8] [9] [10] [11] Reversibility of dilation to aprikalim was tested after a 30-minute exposure to and after washout of glibenclamide. Bradykinin (BK) (10 Ϫ12 to 10 Ϫ6 mol/L), an endotheliumdependent vasodilator, was tested in the presence of L-NAME and indomethacin. 8 Vasodilation to sodium nitroprusside (SNP) (10 Ϫ10 to 10 Ϫ4 mol/L) or papaverine (10 Ϫ4 mol/L), endothelium-independent dilators, was also tested. In some vessels, diazoxide (10 Ϫ8 to 10 Ϫ4 mol/L, another K ATP opener) was also used.
Hypoxia Induction
Hypoxic conditions were produced by bubbling Krebs solution with 5% CO 2 and 95% N 2 gas in a covered vessel chamber. Vascular responses to two consecutive 15-minute periods of hypoxia separated by 60 minutes of intervening normoxia were examined in the absence and presence of inhibitors or denudation. Denudation was confirmed by a reduction in dilation to ADP (10 Ϫ5 mol/L) to Ͻ10% (after Ϫ4Ϯ7% versus before 85Ϯ6%, PϽ0.05) and preserved dilation to SNP (10 Ϫ4 mol/L; after 97Ϯ2% versus before 99Ϯ1%, PϭNS). 7, 11 Responses to aprikalim were also studied before and after hypoxia.
Measurement of Vascular Smooth Muscle Membrane Potential
We measured resting membrane potential (E m ) of vascular smooth muscle cells (VSMCs) and changes in E m to aprikalim or hypoxia, as described previously. 8, 9, 13 Briefly, pressurized HCAs were impaled from the adventitial surface with a glass microelectrode (40 to 90 M⍀ impedance, filled with 3 mol/L KCl) and connected to a high-impedance biological amplifier (Axoclamp, Axon Instruments).
Reverse Transcription-Polymerase Chain Reaction Analysis
From each subject, 5 to 10 HCAs of 1 to 2 mm in length were isolated. Extraction and isolation of mRNA was achieved with oligo(dT) 25 -linked magnetic beads (Dynal), and first-strand cDNA was synthesized from mRNA using Ready-To-Go You-Prime FirstStrand Beads (Amersham Biosciences) according to established protocols. 14 Reverse transcription was initiated by addition of 0.5 g Oligo(dT) 15 Primer (Promega) at 37°C for 75 minutes. Protocols were performed using 1 L of the cDNA in 30 L reaction containing 0.2 mol/L of each primer specific for K ATP , 200 mol/L of each dNTP, and 0.7 U of Taq polymerase (PCR Supermix, Life Technologies). Primers were used for detection of the inwardly rectifying Kir6.1 (expected product, 737 bp) and Kir6.2 (636 bp) and the sulfonylurea receptors SUR1 (134 bp) and SUR2A/2B (451/312 bp), as described before. 15, 16 The primers for SUR2A/2B were designed to identify both SUR2A and SUR2B. Cycling conditions were as follows: for Kir6.1 and 6.2, 96°C, 3 minutes, 40 cycles (96°C, 15 seconds; 55°C, 30 seconds; 72°C, 78 seconds) and 72°C, 7 minutes; and for SUR1 and SUR2A/2B, 94°C, 3 minutes, 40 cycles (94°C, 30 seconds; 58.8°C, 1 minute; 72°C, 1 minute) and 72°C, 7 minutes. An aliquot (10 L) of reverse transcription-polymerase chain reaction (RT-PCR) products was analyzed on 2% TEA agarose gels (Life Technologies). PCR products were visualized by staining with ethidium bromide with ultraviolet transillumination. In the experiments with no or faint expression, a second PCR was also conducted to confirm the results. Negative controls lacking cDNA or reverse transcriptase during cDNA synthesis did not amplify any products, indicating lack of contamination with genomic DNA.
Immunohistochemistry
Small pieces (Ϸ1 mm 3 ) of pectinate muscle were fixed with 4% paraformaldehyde in PBS, infiltrated with 20% sucrose HEPES buffer solution, and frozen in OCT compound. Sections (8-m thick) were immunolabeled with a polyclonal antibody against Kir6.1 protein (dilution 1:250, Santa Cruz Biotechnology, Inc). Immunostains were visualized by using avidin-biotin horseradish peroxidase visualization systems (Vectastain Universal Quick kit, Vector Laboratories). As a control for nonspecific binding, the primary antibody was omitted.
Statistical Analysis
Vasodilations to aprikalim, hypoxia, and BK are expressed as percent dilation, with 100% representing the change in diameter to SNP (10 Ϫ4 
Results
Two hundred HCAs with a passive internal diameter of 100Ϯ3 m (range, 30 to 271 m) were dissected. Patient demographics are summarized in Table 1 . 
Myocardial infarction 39
Congestive heart failure 29
None of the above 12
Data are meanϮSD. n indicates the number of patients studied.
Mechanism of Hypoxic Vasodilation
Hypoxia produced a gradual but potent vasodilation in HCAs (Figure 1 ; 25Ϯ6, 56Ϯ7, and 75Ϯ5% at 5, 10, and 15 minutes, respectively; nϭ29). The reduction in PO 2 was achieved within 5 minutes with minimal change in PCO 2 or pH. On reoxygenation, vascular tone recovered rapidly to resting levels after transient peak dilation at 1 minute (79Ϯ5%). PO 2 , PCO 2 , and pH returned to original levels within 5 minutes. No change in diameter was observed during normoxia of similar duration (nϭ9). Vessels exposed to two consecutive 15-minute periods of hypoxia separated by a 60-minute period of intervening normoxia demonstrated similar degrees of vasodilation (data not shown, PϭNS, nϭ6). Treatment with L-NAME did not alter vasodilation to hypoxia (75Ϯ7 versus control 87Ϯ9%, PϭNS at 15 minutes, nϭ6). Indomethacin potentiated dilation only at 5 minutes (59Ϯ10 versus control 24Ϯ10%, PϽ0.05). Endothelial removal had no effect (68Ϯ10 versus control 75Ϯ14%, PϭNS at 15 minutes, nϭ4). Thus, the endothelium is not critical for hypoxic vasodilation of HCAs.
Glibenclamide reduced hypoxia-induced vasodilation (Figure 2A ; 27Ϯ6 versus control 65Ϯ7%, PϽ0.005 at 15 minutes, nϭ12). The reduced response to hypoxia observed in the presence of glibenclamide could conceivably be the result of impaired K ATP function or an inability of K ATP to respond to a second episode of hypoxia. Dilation to aprikalim was similar before and after exposure to hypoxia (data not shown, PϭNS, nϭ8). Therefore, it is unlikely that hypoxia alters K ATP activation during a subsequent period of hypoxia.
K ATP -Mediated Vasodilation
We next tested whether K ATP activation can dilate HCAs. Aprikalim produced potent vasodilation in a concentrationdependent manner with Ϫlog[ED 50 ] value of 7.0Ϯ0.2 (vehicle produced no dilation; data not shown). Glibenclamide inhibited dilation to aprikalim ( Figure 2B ; maximum dilation, 22Ϯ6 versus control 90Ϯ4%, PϽ0.05, nϭ5) and attenuated diazoxide-induced dilation (maximum dilation, 13Ϯ5 versus control 44Ϯ4%, PϽ0.05, nϭ6) but had no effect on dilation to SNP (maximum dilation, 86Ϯ5 versus control 87Ϯ6%, PϭNS, nϭ6) or papaverine (maximum dilation, 95Ϯ2 versus control 92Ϯ4%, PϭNS, nϭ6). We previously showed that this dose of glibenclamide has no effect on the dilation to BK 8 or shear stress. 10 Aprikalim-induced dilation was unchanged by L-NAME (Ϫlog[ED 50 ], 7.1Ϯ0.4 versus control 7.0Ϯ0.5, PϭNS; maximum dilation, 93Ϯ3 versus control 93Ϯ3%, PϭNS, nϭ5), indomethacin (Ϫlog[ED 50 ], 6.9Ϯ0.4 versus control 7.0Ϯ0.5, PϭNS; maximum dilation, 87Ϯ6 versus control 93Ϯ3%, PϭNS, nϭ5), or endothelial denudation (Ϫlog[ED 50 ], 6.4Ϯ0.3 versus control 6.2Ϯ0.3, PϭNS; maximum dilation, 96Ϯ2 versus control 93Ϯ4%, PϭNS, nϭ4). Thus, dilation to selective K ATP opening with aprikalim is independent of the endothelium in HCAs.
Membrane Hyperpolarization to Aprikalim and Hypoxia
We measured the change in VSMCs E m to K ATP activation. Figure 3A shows a typical example of the effect of aprikalim Hypoxia produced a prominent and reversible vasodilation of HCAs (nϭ29; male, 90%; age, 61Ϯ15 years; coronary artery disease, 93%; myocardial infarction, 7%; hypertension, 27%; hypercholesterolemia, 17%; DM, 30%; congestive heart failure, 7%). After reoxygenation, the diameter returned to original levels. No change in vascular diameter was observed during normoxic experiments of similar duration (nϭ9; male, 78%; age, 64Ϯ12 years; coronary artery disease, 89%; myocardial infarction, 22%; hypertension, 33%; hypercholesterolemia, 44%; DM, 44%; congestive heart failure, 22%). ; age, 67Ϯ9 years; coronary artery disease, 92%; myocardial infarction, 25%; hypertension, 58%; hypercholesterolemia, 17%; DM, 42%; congestive heart failure, 8%. B, Vessels dilated to aprikalim (10 Ϫ10 to 10 Ϫ5 mol/L) in a glibenclamide-sensitive (10 Ϫ6 mol/L) manner (#PϽ0.05 vs control, nϭ5). Patient demographics: male, 60%; age, 51Ϯ25 years, coronary artery disease, 80%; myocardial infarction, 20%; hypertension, 0%; hypercholesterolemia, 0%; DM, 20%; congestive heart failure, 40%.
on E m of a VSMC in a cannulated and pressurized HCAs. Aprikalim produced hyperpolarization from a resting E m of Ϫ52 to Ϫ54, Ϫ58, and Ϫ85 mV at 10 Ϫ9 , 10
Ϫ7
, and 10 Ϫ5 mol/L, respectively, in a dose-dependent fashion. BK did not additionally hyperpolarize the VSMC, indicating a near-maximal hyperpolarization. Increases in extraluminal KCl depolarized the VSMC. Summary data are shown in Figure 3B .
To link vasodilator and electrophysiological observations, we simultaneously measured changes in vessel diameter and E m during hypoxia. Figure 3C shows that hypoxia elicited dilation and hyperpolarization that were attenuated by glibenclamide (maximum dilation, 46Ϯ5 versus control 73Ϯ7%, PϽ0.05, nϭ5).
K ATP Expression in the Coronary Microcirculation
In HCAs, RT-PCR detected transcripts for Kir6.1 and SUR2B from all subjects tested ( Figures 4A and 4B) , whereas mRNA for either Kir6.2, SUR1, or SUR2A was detected in only one subject.
Positive staining for Kir6.1 was observed by immunohistochemistry in HCAs ( Figure 4C ). VSMCs showed strong immunostaining for Kir6.1 protein, but endothelial cells were only faintly immunostained. This same pattern was observed in each of the three subjects.
Influence of Disease on K ATP -Mediated Vasodilation
By multivariate analysis, only the presence of DM predicted the impaired vasodilation to hypoxia (Table 2 ). ANACOVA also indicated that DM was correlated with reduced dilation to hypoxia independent of other risk factors and conditions ( Figure 5A ; maximum dilation, DM(ϩ) 56Ϯ8 versus DM(Ϫ) 85Ϯ5%, PϽ0.01, nϭ30).
DM was also identified by multivariate analysis and ANACOVA as the only independent predictor of reduced dilation to aprikalim (Table 2 and Figure 5B ; Ϫlog[ED 50 ], DM(ϩ) 6.3Ϯ0.3 versus DM(Ϫ) 7.3Ϯ0.2, PϽ0.05; maximum dilation, DM(ϩ) 90Ϯ2 versus DM(Ϫ) 96Ϯ1%, PϽ0.05; nϭ34).
In contrast to hypoxia and aprikalim, no cardiovascular risk factors were associated with alterations in dilation to SNP or in endothelium-derived hyperpolarizing factor-mediated vasodilation to BK 8 by multivariate analysis and ANACOVA (SNP, Figure 5C ; Ϫlog[ED 50 ], DM(ϩ) 7.1Ϯ0.3 versus DM(Ϫ) 7.1Ϯ0.2, PϭNS; maximum dilation, DM(ϩ) 97Ϯ2 versus DM(Ϫ) 92Ϯ1%, PϭNS, nϭ35) and (BK, Figure 5D ; Ϫlog[ED 50 ], DM(ϩ) 7.6Ϯ0.2 versus DM(-) 7.6Ϯ0.1, PϭNS; maximum dilation, DM(ϩ) 92Ϯ5 versus DM(Ϫ) 90Ϯ3%, PϭNS, nϭ37). Therefore, it is unlikely that impaired dilation to aprikalim or hypoxia in patients with DM is attributable to a nonspecific reduction in dilation.
Resting E m from diabetic patients (nϭ14) and nondiabetic patients (nϭ35) was similar (DM Ϫ47Ϯ2 versus non-DM Ϫ47Ϯ1 mV, PϭNS). No risk factor was predictive of an alteration in resting E m by either multivariate analysis or ANACOVA. Spontaneous vascular tone was likewise not correlated with disease (data not shown).
Although we were not able to obtain full medication information, it is likely that some diabetic patients were treated with sulfonylureas, which may have influenced dilation to aprikalim. When diabetic patients were divided Fifty-five-year-old man with coronary artery disease. B, Summary data from 6 vessels show that aprikalim hyperpolarizes VSMCs in a dose-dependent manner (#PϽ0.05 vs baseline, nϭ6). Patient demographics: male, 83%; age, 65Ϯ10 years; coronary artery disease, 67%; myocardial infarction, 0%; hypertension, 33%; hypercholesterolemia, 33%; DM, 17%; congestive heart failure, 0%. C, After membrane depolarization and vasoconstriction with acetylcholine, hypoxia induced hyperpolarization (#PϽ0.05 vs baseline, nϭ5) and vasodilation. Glibenclamide attenuated both vasodilation and hyperpolarization to hypoxia (*PϽ0.05 vs without glibenclamide, nϭ5). Patient demographics: male, 100%; age, 62Ϯ12 years; coronary artery disease, 80%; myocardial infarction, 20%; hypertension, 60%; hypercholesterolemia, 0%; DM, 40%; congestive heart failure, 20%.
according to the subtype, hypoxia-induced vasodilation was similarly reduced in both type 1 (nϭ8) and type 2 (nϭ8) DM compared with non-DM controls (nϭ25) ( Figure 6A ; maximum dilation, type 1 21Ϯ3 and type 2 45Ϯ13 versus non-DM 81Ϯ5%, respectively, PϽ0.05). Vasodilation to aprikalim was similarly reduced in both type 1 (nϭ6) and type 2 (nϭ8) DM compared with the non-DM group (nϭ31) ( Figure 6B ; Ϫlog[ED 50 ], type 1 6.3Ϯ0.2 and type 2 6.1Ϯ0.2 versus non-DM 7.1Ϯ0.1, PϽ0.05 respectively; maximum dilation, type 1 84Ϯ12 and type 2 91Ϯ2 versus non-DM 95Ϯ1%, respectively, PϭNS). In addition, aprikalim-induced dilation was unchanged before and after a 30-minute exposure and washout of glibenclamide (maximum dilation, after 97Ϯ2 versus before 99Ϯ0%; Ϫlog[ED 50 ], after 7.4Ϯ0.3 versus before 7.3Ϯ0.3, PϭNS, nϭ6), indicating reversible inhibition of glibenclamide.
DM could alter non-K ATP -mediated mechanisms of hypoxic dilation. Glibenclamide reduced hypoxic vasodilation less in arterioles from subjects with DM (maximum dilation, 27Ϯ7 versus control 52Ϯ10%, PϽ0.05, nϭ6) than from subjects without DM (maximum dilation, 26Ϯ10 versus control 78Ϯ7%, PϽ0.05, nϭ6). However, the residual dilation after glibenclamide was similar, suggesting that the major impairment in hypoxic dilation in DM is attributable to the K ATP -sensitive component.
Discussion
This study is the first to describe impaired vasodilation to hypoxia and K ATP activation in HCAs from patients with DM. The major new findings are 5-fold. First, hypoxia induces a .1 in all subjects tested, whereas mRNA for Kir6.2 was seen only in one subject. B, Left, transcripts for SUR1 were faintly detected in one of three vessels. Right, all subjects expressed mRNA for SUR2B, whereas one subject showed SUR2A mRNA expression. DNA size markers are indicated on the left, and each expected product size is on the right. Subject 1 was a 79-year-old woman with hypertension; subject 2 was a 65-year-old man; and subject 3 was a 55-year-old man. These patients had no coronary artery disease or DM. C, Representative photomicrograph of atrial tissue immunostained with a polyclonal antibody against Kir6.1. Strong positive staining (brown tint) was seen in VSMCs and modest staining in endothelial cells. Magnification ϫ60 (scale barsϭ10 m). Tissue was from a 47-year-old woman without coronary artery disease or DM. potent and endothelium-independent vasodilation. Second, K ATP activation dose-dependently hyperpolarizes VSMCs and induces vasodilation. Third, the mechanism of hypoxiainduced vasodilation involves opening of K ATP . Fourth, vasodilation to both hypoxia and K ATP stimulation is impaired in both type 1 and type 2 DM. Finally, mRNA and protein for K ATP subunits are present in HCAs, K ATP possibly being comprised of SUR2B and Kir6.1. These findings indicate that in DM, vasodilator function associated with K ATP opening is reduced in the human coronary microcirculation.
Vasodilation to Aprikalim
Human vessels can dilate in response to K ATP openers 17, 18 ; however, the mechanism is not clear. Vasodilations to both aprikalim and diazoxide were attenuated by glibenclamide, but dilations to SNP, papaverine, BK, 8 and shear stress 10 were not affected. Patch-clamp analysis shows that glibenclamide blocks K ATP current in response to K ATP openers in VSMCs from human coronary arteries. 19 These findings indicate that K ATP openers dilate HCAs by selectively opening K ATP . We demonstrated that aprikalim-induced vasodilation was not affected by inhibiting NO synthase or cyclooxygenase using doses of antagonists that are effective in human vessels. 8, 10, 11, 20, 21 This is similar to findings in rat cerebral and porcine coronary arterioles. 2, 4 However, it contrasts with observations made in small cerebral arteries of diabetic rats. 5
Hypoxia-Induced Vasodilation
Several animal studies have reported that K ATP opening mediates hypoxia-induced vasodilation in conduit and resistance arteries. 1,2 However, inhibition of K ATP is reported to be ineffective in attenuating hypoxia-induced vasorelaxation in rabbit aorta and porcine coronary arteries. 22, 23 In the present study, glibenclamide significantly reduced hypoxic vasodilation in HCAs, suggesting that K ATP are involved in transducing vascular signals to reduced tissue oxygen concentrations in the human heart.
In the present study, NO did not contribute to hypoxiainduced vasodilation. However, results from animal studies are varied, some indicating an important role for NO in isolated guinea pig hearts and rabbit coronary arteries 22, 24 and others showing no effect in porcine cerebral arterioles and small coronary arteries. 2, 25 The contribution of NO varies depending on the vascular bed, species, vessel size (conduit or resistance arteries), or experimental preparations. This highlights the importance of examining responses in vessels from human subjects.
An enhanced dilation to hypoxia at 5 minutes was observed in the presence of indomethacin. A similar augmentation has been described in porcine, monkey, and human coronary arteries. 20, 26 Human endothelial cells showed the release of vasoconstrictor prostaglandins during the early phase of hypoxia. 21 Hypoxia-induced vasodilation is endothelium-dependent in porcine small coronary arteries (Ϸ170 m diameter) 2 , whereas it is endothelium-independent in porcine coronary arteries (Ϸ1 mm diameter). 27 In human conduit coronary arteries, Siegel et al 28 reported that the contribution of endothelium to hypoxia-induced vasodilation is 49%, whereas Toda et al 20 reported no alteration after endothelial denudation. Our study identifies a unique response in the coronary microcirculation. We observed a direct hyperpolarizing and vasorelaxing effect of hypoxia on coronary smooth muscle cells that is endothelium-independent.
K ATP Expression in the Coronary Microcirculation
The molecular profile of vascular K ATP , especially in the coronary microcirculation, is not fully determined. Part of the difficulty arises from the complex nature of the channel, in that K ATP are octamers composed of four Kir6.0 subfamily subunits (Kir6.1 and 6.2) and four SUR subunits (SUR1 and SUR2), combined into a heteromultimeric complex. K ATP in VSMCs are proposed to comprise SUR2B and Kir6.1, based on similar electrophysiological characteristics of the reconstituted channels to the native one. 29 A recent study using a genetic mouse model lacking Kir6.1 showed the absence of K ATP activity in VSMCs, suggesting a critical role of Kir6.1 for vascular K ATP activity. 30 It is also reported that microvascular endothelial cells in the guinea pig heart express K ATP composed of SUR2B and Kir6.1 and/or Kir6.2 subunits. 31 These observations are consistent with our results showing the mRNA expression of Kir6.1, Kir6.2, and SUR2B and the localization of Kir6.1 protein in HCAs. RT-PCR revealed the expression of SUR1 and SUR2A in only one of three vessels tested. This may be attributed to presence of inflammatory cells or perivascular cells, including myocytes and neurons, which express SUR1 and SUR2A, 31, 32 or a compensatory upregulation of this channel subunit. Additional studies should examine these possibilities.
DM and Impairment of K ATP -Mediated Vasodilation
The mechanism of impaired vasodilation to K ATP activation is not clear. We found impaired dilation to aprikalim and hypoxia but not to SNP and BK in HCAs from subjects with diabetes. Thus, the impairment seems to be specific for K ATP mechanisms, because VSMC relaxation followed by decrease in intracellular Ca 2ϩ concentration either by cGMP production attributable to NO (SNP) or by membrane hyperpolarization through Ca 2ϩ -activated K ϩ channel activation, as occurs with BK, 8 was not reduced. As with other studies, [3] [4] [5] we observed reduced vasodilation to K ATP opening. In contrast to our observations, an enhanced vasodilation to aprikalim was seen in diabetic canine coronary arterioles. 6 This discrepancy might be dependent on the disease duration (months to years in rat models and humans versus hours to days in canine models) and/or the different experimental methods (in vitro versus in vivo).
Potential Problems
Sulfonylureas are clinically prescribed K ATP blockers. In clinically relevant concentrations, glibenclamide increases basal coronary resistance 33, 34 and attenuates vasodilation to hypoxia in the heart. 1,2 Because of the nature of the IRB approval, we are unable to retrospectively identify medication use. Some diabetic patients may have been treated with sulfonylureas, and it is possible that effect of these medicines could be responsible for the reduced dilation to aprikalim and hypoxia. For two reasons, we believe that such an effect, if present, was small and did not influence our interpretation of the results. First, the effect of aprikalim is fully reversible, because rinsing vessels with Krebs solution eliminated the inhibitory effect of glibenclamide on aprikalim-induced vasodilation. Multiple rinses during dissection and before experimentation would be expected to remove previously administered sulfonylureas. Second, the impaired dilation to aprikalim or hypoxia was seen in both type 1 and type 2 DM. It is unlikely that type 1 diabetic patients were treated with sulfonylureas. These reasons make it unlikely that retained or chronic effects of diabetic medications contributed to the impaired dilation to hypoxia and aprikalim.
In the present study, glibenclamide did not completely abolish vasodilation to hypoxia. Other factors may be involved in hypoxic dilation, as reported in other tissues, including Ca 2ϩ -activated K ϩ channels and cytochrome P450 metabolites, 25, 35 decrease in tissue pH, 36 adenosine receptor activation, 37 or production of lactate. 38 An insufficient dose of glibenclamide is not likely, because the same dose markedly inhibited dilation to aprikalim. It is unlikely that non-K ATP mechanisms are responsible for the reduced response to hypoxia, because the residual dilation to hypoxia after glibenclamide is similar in both DM and non-DM subjects.
Clinical Implications
DM is associated with an increased risk of cardiovascular and cerebrovascular morbidity and mortality. In addition to the more accelerated conduit coronary atherosclerosis, DM is associated with diffuse microvascular disease. Even for the same degree of atherosclerosis, patients with DM suffer greater morbidity from ischemia. 39 Clinical studies indicate that DM impairs myocardial perfusion. 40, 41 Our results dem- Figure 6 . Comparison of dilator responses in patients with type 1 and type 2 DM. A, Hypoxia-induced dilation was impaired in both type 1 (nϭ8) and type 2 (nϭ8) DM patients (#PϽ0.05 vs non-DM, nϭ25). B, Aprikalim-induced dilation was also impaired in type 1 (nϭ6) and type 2 (nϭ8) DM patients (#PϽ0.05 vs non-DM, nϭ31).
onstrate impaired dilation to K ATP opening in DM. This could impede vasodilator responses, especially during ischemia or hypoxia in patients with DM, possibly contributing to increased myocardial ischemic injury in these patients.
In summary, in HCAs, hypoxia-induced vasodilation is mediated largely by activation of K ATP . Vasodilations to hypoxia and direct K ATP opening are impaired in DM. This coronary microcirculatory dysfunction may contribute to the higher cardiovascular mortality and morbidity in DM.
